Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 30,000 Class A shares of the company on 08/07/2024, with an aggregate market value of $213,000. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a three-month period where a total of 200,000 shares were sold for gross proceeds of $1,618,500.

Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 30,000 Class A shares of the company on 08/07/2024, with an aggregate market value of $213,000. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a three-month period where a total of 200,000 shares were sold for gross proceeds of $1,618,500.